Oncology – Urological
RCT: Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer.
16 May, 2022 | 02:35h | UTCEditorial: Robotic Surgery for Bladder Cancer – JAMA
Commentary on Twitter
In this trial, robot-assisted surgery vs open surgery for radical cystectomy among patients with #bladdercancer resulted in a statistically significantly greater number of days alive and out of the hospital. https://t.co/icPLiKH0Lf
— JAMA (@JAMA_current) May 15, 2022
AUA/ASTRO Guideline: Clinically localized prostate cancer.
13 May, 2022 | 11:10h | UTCHomepage: Clinically Localized Prostate Cancer: AUA/ASTRO Guideline – American Urological Association
Part I: Introduction, Risk Assessment, Staging and Risk-Based Management
Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
Part III: Principles of Radiation and Future Directions
Related:
Therapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality
Radical prostatectomy versus deferred treatment for localised prostate cancer – Cochrane Library
Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.
10 May, 2022 | 10:32h | UTC
First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment.
6 May, 2022 | 10:27h | UTC
Review: A global approach to improving penile cancer care.
5 May, 2022 | 09:55h | UTCA global approach to improving penile cancer care – Nature Reviews Urology (if the link is paywalled, try this one)
RCT: Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
3 May, 2022 | 10:38h | UTC
Commentary on Twitter
🆕 #JCO #ClinicalTrialUpdate: ARCHES trial – 📈 Enzalutamide + ADT improved OS in men with metastatic horomone-sensitive #ProstateCancer 👉 https://t.co/FQ1lViCTZz #PCSM @AarmstrongDuke pic.twitter.com/fLs6PdFYlr
— Journal of Clinical Oncology (@JCO_ASCO) April 27, 2022
Guideline: Management of small renal masses.
28 Apr, 2022 | 10:36h | UTCSee also: Summary of Recommendations
Review: Germline testing and genetic counselling in prostate cancer.
28 Apr, 2022 | 08:11h | UTCGermline testing and genetic counselling in prostate cancer – Nature Reviews Urology (if the link is paywalled, try this one at PMC)
M-A: Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavorable prostate cancer.
26 Apr, 2022 | 07:51h | UTC
Consensus Statement: Management of patients with advanced prostate cancer.
25 Apr, 2022 | 00:50h | UTC
Commentary on Twitter
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021https://t.co/GjTGPx8IbN@APCCC_Lugano @Silke_Gillessen @AOmlin @AarmstrongDuke @piet_ost @Prof_IanD @DrSpratticus @charlesryanmd @Tilki_De @declangmurphy pic.twitter.com/FU0Fbjf8WZ
— European Urology (@EUplatinum) April 22, 2022
Phase 2 RCT: Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer.
24 Apr, 2022 | 23:53h | UTC
Commentary on Twitter
In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm
— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022
Opinion | Low-grade prostate cancer (Gleason score 6): time to stop calling it cancer.
19 Apr, 2022 | 02:29h | UTCLow-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Commentary: Doctors suggest new names for low-grade prostate cancer – Associated Press
10-year results of a phase 3 RCT: High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer.
19 Apr, 2022 | 01:22h | UTCHigh-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology (link to abstract – $ for full-text)
Endocrine therapies for breast and prostate cancers: Essentials for primary care.
19 Apr, 2022 | 01:14h | UTC
Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with hematuria.
14 Apr, 2022 | 08:16h | UTCSystematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuriahttps://t.co/zB6CHYKprL@stingrai78 @drimranomar @ahmostafid @soukup_viktor @Phil_Violette pic.twitter.com/Ouv3lFfRpm
— European Urology (@EUplatinum) April 11, 2022
Cohort Study: Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer.
14 Apr, 2022 | 07:59h | UTCCommentary: Men treated for prostate cancer have increased fracture risk, yet few complete DXA screening – HealthImaging
Commentary on Twitter
In this cohort study, osteoporosis screening rates for over 50,000 elderly men with prostate cancer receiving hormonal therapy nationwide were very low; men who were screened were less likely to suffer major fractures in follow-up. https://t.co/RMz1bvEgiA
— JAMA Network Open (@JAMANetworkOpen) April 1, 2022
RCT: Effects of abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer.
11 Apr, 2022 | 01:23h | UTCAbiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design – The Lancet (link to abstract – $ for full-text)
Systematic Review: Diagnostic and prognostic factors in patients with prostate cancer.
7 Apr, 2022 | 08:16h | UTCDiagnostic and prognostic factors in patients with prostate cancer: a systematic review – BMJ Open
Canadian recommendations on prostate cancer screening and early diagnosis.
6 Apr, 2022 | 09:47h | UTCSee also: Summary of changes
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer.
1 Apr, 2022 | 08:30h | UTC
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer.
31 Mar, 2022 | 07:46h | UTC
EAU Guidelines on renal cell carcinoma.
30 Mar, 2022 | 10:19h | UTC
German guidelines for diagnostics and prognostic evaluation in renal cell tumors.
25 Mar, 2022 | 08:25h | UTC
Current management of urachal carcinoma: an evidence-based guide for clinical practice.
22 Mar, 2022 | 08:09h | UTC
RCT: Imaging modality (CT vs. MRI) and frequency (seven scans over 60 months vs. three scans over 36 months) in surveillance of Stage I Seminoma Testicular Cancer.
21 Mar, 2022 | 08:39h | UTCImaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST) – Journal of Clinical Oncology (link to abstract – $ for full-text)